ClinicaliQ Trial Snapshot
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease — Active Not Recruiting • Phase III • NCT06106828.
- Satralizumab injection tested for treating thyroid eye disease by blocking inflammation.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED). Conditions: Thyroid Eye Disease Interventions: Satralizumab, Placebo Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 127 participants